Skip to main content
S&P 5007,520.93-0.38%DOW52,231.89-0.30%NASDAQ25,065.88-0.74%BTC$73,671.00-1.77%ETH$2,057.29-3.16%GOLD$4,059.70+0.73%OIL$86.26+0.26%
Smart Investors Daily
SID Premium
AD

NASDAQ · ADAG

Adagene Inc.

Healthcare · Biotechnology

$2.05

Down-$0.07 (-3.30%)

Updated Nov 11, 2026, 4:06 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
111.61M
P/E ratio
-2.9
Dividend yield
0.00%
52-week range
$1.30 – $4.85
Volume
85.68K
Avg. volume
119.56K

Price performance · ADAG

ADAG price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 10, 2026

ADAG closed at $2.05 after 21 trading sessions, down 16.67% for the selected period.

Last close
$2.05
Period change
-16.67%
Period low
$2.00
Period high
$2.68
Daily close
View OHLC price history
ADAG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 10, 2026$2.12$2.17$2.01$2.0585.68K
Nov 9, 2026$2.10$2.38$2.07$2.12160.6K
Nov 6, 2026$2.11$2.19$1.93$2.00189.03K
Nov 5, 2026$2.24$2.24$2.005$2.02345.33K
Nov 4, 2026$2.49$2.52$2.34$2.41114.85K
Nov 3, 2026$2.25$2.535$2.25$2.35107.35K
Nov 2, 2026$2.52$2.60$2.17$2.29181.78K
Oct 30, 2026$2.67$2.69$2.46$2.5179.69K
Oct 29, 2026$2.65$2.72$2.60$2.68172.57K
Oct 28, 2026$2.75$2.78$2.61$2.67235.91K
Oct 27, 2026$2.48$2.67$2.44$2.58189.23K
Oct 26, 2026$2.42$2.55$2.34$2.4991.2K
Oct 23, 2026$2.43$2.57$2.295$2.41167.17K
Oct 22, 2026$2.24$2.51$2.24$2.44244.22K
Oct 21, 2026$2.55$2.55$2.39$2.4196.53K
Oct 20, 2026$2.30$2.50$2.30$2.5092.71K
Oct 19, 2026$2.04$2.29$2.01$2.29308.8K
Oct 16, 2026$2.40$2.40$2.01$2.06379.6K
Oct 15, 2026$2.31$2.42$2.26$2.40552.48K
Oct 14, 2026$2.35$2.50$2.25$2.29898.86K
Oct 13, 2026$2.73$2.73$2.435$2.46228.89K

Latest ADAG news

The latest Smart Investors Daily articles mentioning ADAG.

Stock researchCompany · Overview

ADAG research

Overview

Company profile and research snapshot.

Company profile

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.00
Implied upside
—
Analysts
14
ADAG recent ratings
DateFirmRatingTarget
Oct 28, 2026Chardan CapitalBuy—
Oct 19, 2026HC Wainwright & Co.Buy—
Sep 14, 2026HC Wainwright & Co.Buy—
Sep 10, 2026Chardan CapitalBuy—
Apr 6, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and SUZHOU, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the dosing of the first patient in a Phase

Yahoo · Oct 27, 2026

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference being held November 9-11, 2026 in Boston, MA. Guggenheim Securities 3rd Annual Healthcare

Yahoo · Oct 25, 2026

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

Adagene (NASDAQ:ADAG) is advancing its masked anti-CTLA-4 antibody, ADG126, also known as muzastotug, in metastatic microsatellite-stable colorectal cancer (MSS CRC) and in a neoadjuvant investigator-sponsored trial in Singapore, Chief Strategy Officer Mickael Chane-Du said during a Chardan conferen

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By